COMPANY ANNOUNCEMENT Inside Information - No. 19, 2021 - 26 October 2021
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces the first order from a new clinical routine customer in Greece.
The customer is a hospital located in the Athens area. The hospital is a public hospital with more than 700 beds and is one of Greece's leading university hospitals. The hospital has placed the first order of suPARnostic® TurbiLatex for its Roche cobas 701 system. The hospital has previously also been a participant in the SAVE-MORE COVID-19 study using the suPARnostic® Quick Triage product.
ViroGates has revamped its disclosure policy to introduce stricter criteria for announcing clinical routine customers. ViroGates will announce a clinical customer once the customer has either 1) placed the second purchase order for clinical use or 2) placed the first purchase order with a clear intention of placing future orders for clinical use. If a customer has not placed a clinical order in the previous twelve months, ViroGates will consider the customer churned. To ensure transparency, ViroGates will include information about the number of clinical routine customers in all future financial reports (interim, half-year and annual reports) based on the definition above.
Jakob Knudsen, Chief Executive Officer of ViroGates, said:”We are happy to add another clinical customer in Greece. We have worked with the customer on various projects and are excited to learn that this has turned into clinical use. Greece has adopted suPARnostic® TurbiLatex very well, and we are happy to see that the product is used in general acute care triage decisions.”
The announcement can be found at: https://www.virogates.com/investor/announcements
For further information, please contact:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: email@example.com
Västra Hamnen Corporate Finance
Tel. (+46) 40 200 250, email: firstname.lastname@example.org
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 750 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length-of-stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
- Jakob Knudsen, CEO, +45 2226 1355, email@example.com
© Ritzau Denmark, source Ritzau English Regulatory Releases